CCL2 and myalgic encephalomeyelitis/chronic fatigue syndrome: Substances blocking MCP-1 are under testing for treatment of neuroinflammation, cardiovascular inflammation (Franca et al., 2017), inflammatory disorders (Zoja et al., 2015) and might thus even be of interest in FM and CFS if our findings of increased MCP-1 are confirmed and found to have a function in pathogeneses.